Longitudinal risk of serious infections in patients with inflammatory arthritis on immunomodulating therapy compared to controls
Patients with IA starting their first b/tsDMARD between 2009 and 2018 had a consistently higher 12-month risk of serious infection compared with controls. No change in the risk of serious infection across time cohorts of b/tsDMARD initiation was observed, nor during the treatment course.
Authors
- Tore Kristian Kvien (ORCID: https://orcid.org/0000-0002-8441-3093)
- Till Uhlig (ORCID: https://orcid.org/0000-0002-6881-9552)
- Siri Lillegraven (ORCID: https://orcid.org/0000-0003-3615-0134)
- Sella Aarrestad Provan (ORCID: https://orcid.org/0000-0001-5442-902X)
- Ingrid Christensen (ORCID: https://orcid.org/0000-0002-8429-8152)
- Joseph Sexton
Institutions
- University of Oslo (NO)
- University of Inland Norway (NO)
- Diakonhjemmet Hospital (NO)
Publication Details
- Journal
- Rheumatology Advances in Practice
- Published
- 2024-12-18
- DOI
- https://doi.org/10.1093/rap/rkaf017
- Citations
- 3
- Primary Topic
- Spondyloarthritis Studies and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.41
Funders
- Pfizer
- Helse Sør-Øst RHF